Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Monoclonal antibodies (mAbs) targeting HER2 are used for breast cancer but face limitations due to low efficacy and resistance.
• HER2-targeted therapies can be improved by overcoming resistance mechanisms and enhancing antitumor responses.

Purpose of the Study:

• To evaluate the efficacy of combining mAbs against different HER2 epitopes in three-dimensional (3D) mammary cell models.
• To compare the effects of single mAbs versus antibody combinations on HER2-overexpressing cells, particularly in response to growth factors.

Main Methods:

• Utilized 3D mammary cell culture models to mimic in vivo conditions.
• Performed in vitro assays and computational image analyses to assess invasive growth and cellular phenotypes.
• Investigated the impact of growth factors on HER2-overexpressing spheroids and the ability of mAb combinations to reverse these effects.

Main Results:

• Combinations of mAbs targeting distinct HER2 epitopes demonstrated superior inhibition of invasive growth compared to single mAbs.
• Antibody combinations effectively reversed growth factor-induced phenotypes, including reduced apoptosis and increased invasiveness, in HER2-overexpressing spheroids.
• Computational image analysis provided quantitative insights into the anti-invasive effects of mAb combinations.

Conclusions:

• Combining mAbs against different HER2 epitopes represents a promising therapeutic strategy to enhance antitumor effects in HER2-overexpressing breast cancers.
• This approach may overcome resistance mechanisms and improve the clinical efficacy of existing HER2-targeted immunotherapeutics.
• The findings suggest that mAb combinations can negate the pro-invasive biological effects of growth factors on HER2-driven cancer cells.